Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Fluorouracil / salicylic acid (Actikerall®) is recommended as an option for use within NHS Wales for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) in immunocompetent adult patients. |
|||
|
|||
Medicine details |
|||
| Medicine name | fluorouracil/salicylic acid (Actikerall®) | ||
| Formulation | 0.5%/10% cutaneous solution | ||
| Reference number | 1233 | ||
| Indication | Topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) in immunocompetent adult patients |
||
| Company | Almirall Ltd | ||
| BNF chapter | Skin | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1012 | ||
| NMG meeting date | 28/03/2012 | ||
| AWMSG meeting date | 09/05/2012 | ||
| Ratification by Welsh Government | 19/06/2012 | ||
| Date of issue | 21/06/2012 | ||
| Date of last review | 30/08/2016 | ||